A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ublituximab (BRIUMVI)

Ublituximab targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

First FDA approval2022-12-28
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Ublituximab used for?

Ublituximab targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

Is there a generic for Ublituximab?

No. Ublituximab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ublituximab?

NADAC pricing data not currently available for this drug.

Is Ublituximab on the FDA shortage list?

No. Ublituximab is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

CD20-directed Cytolytic Antibody6 alternatives in D1
01
Obinutuzumab
Brand: Gazyva
Lowest NADAC
0Generic mfrs
$15.0MCY24 Part D spend
Compare →
02
Ocrelizumab
Brand: OCREVUS
Lowest NADAC
0Generic mfrs
$319.4MCY24 Part D spend
Compare →
03
Ofatumumab
Brand: ARZERRA
$24459.32Lowest NADAC
0Generic mfrs
$975.4MCY24 Part D spend
Compare →
04
Rituximab
Brand: Rituxan
Lowest NADAC
0Generic mfrs
$61.6MCY24 Part D spend
Compare →
05
Rituximab-Abbs
Brand: Truxima
Lowest NADAC
0Generic mfrs
$36.2MCY24 Part D spend
Compare →
06
Rituximab-Arrx
Brand: Riabni
Lowest NADAC
0Generic mfrs
$11.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.